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Abstract
We conducted a study to assess the effect of rosuvastatin use on fibrinolysis
in patients with previous venous thromboembolism (VTE). This was a post
hoc analysis within the STAtins Reduce Thrombophilia (START) study
(NCT01613794). Plasma fibrinolytic potential, fibrinogen, plasmin inhibi-
tor, plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable
fibrinolysis inhibitor (TAFI) were measured before and after four weeks of
rosuvastatin or no treatment in participants with prior confirmed VTE,
after ending anticoagulant therapy. In the non-rosuvastatin group
(n = 121), plasma fibrinolytic potential and individual fibrinolysis parame-
ters did not change at the end of the study versus the baseline, whereas in
the rosuvastatin group (n = 126), plasma fibrinolytic potential increased:
the mean clot lysis time decreased by 875 min (95% CI 138 to 372),
and plasmin inhibitor levels and TAFI activity were lower at the end of the
study (005 U/ml; 95% CI 007 to 002 and 477%; 95% CI 681
to 273, respectively). PAI-1 levels did not change and fibrinogen levels
were 017 g/l (95% CI 004–029) higher. In participants with prior VTE,
rosuvastatin use led to an increased fibrinolytic potential compared with
non-statin use. Our findings support the need for further studies on the
possible role for statins in the secondary prevention of VTE.
Keywords: venous thromboembolism, fibrinolysis, blood coagulation tests,
fibrin clot lysis time, HMG-CoA reductase inhibitors.
HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase
inhibitors, more commonly known as statins, exert cardio-
vascular protective effects which are independent of LDL-c-
holesterol lowering, including antithrombotic effects.1 A
meta-analysis of 36 studies, including 23 randomised stud-
ies, showed a 15% risk reduction of statin use on first
venous thromboembolism (VTE) events compared to pla-
cebo or no treatment.2 Antithrombotic effects seem to be
most robust for rosuvastatin.3 However, the exact mecha-
nism behind the antithrombotic effects of statins is not
completely unraveled.4,5 The fibrinolytic system, which plays
an important role in dissolving thrombi, is likely to con-
tribute to the antithrombotic effects. In two large observa-
tional studies, hypofibrinolytic activity has been linked to
an increased risk of VTE.6,7 Also, statin use has been
associated with lower levels of D-dimer and other fibrin
degradation products (FDPs).8 During fibrinolysis, the inac-
tive proenzyme plasminogen is converted by tissue plas-
minogen activator (t-PA) or urokinase-type plasminogen
activator (u-PA) to the active enzyme plasmin.9,10 Several
inhibitors of fibrinolysis are known, such as plasminogen
activator inhibitor-1 (PAI-1), which can inhibit these con-
verting enzymes. The activated plasmin degrades fibrin into
FDPs, and is inhibited by plasmin inhibitor. Additionally,
thrombin converts fibrinogen into fibrin, but also activates
thrombin-activatable fibrinolysis inhibitor (TAFI). A better
understanding of the exact effect of statins on fibrinolysis
will help in determining the position of statins in the treat-
ment of prevention of (recurrent) VTE without increased
risk of haemorrhage.
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To test the effects of rosuvastatin use on fibrinolysis, we
performed a post hoc analysis of the START (STAtins Reduce
Thrombophilia) study. Plasma fibrinolytic potential as well
as fibrinogen, plasmin inhibitor (also called a2-antiplasmin),
PAI-1 and TAFI were determined in blood samples before
and after four weeks of rosuvastatin or no treatment in a
population suspected to be hypercoagulable. Notably, D-
dimer levels have been measured and analysed previously.11
Materials and methods
Study design
This was a post hoc analysis within the STAtins Reduce Throm-
bophilia (START) study, a collaboration of three anticoagula-
tion clinics in the Netherlands (Star-shl in Rotterdam, the
Leiden Anticoagulation Clinic and Atalmedial, Hoofddorp), of
which the design was previously described (clinical trials.gov
NCT01613794).11 This study was performed in accordance
with the Declaration of Helsinki, all participants gave written
informed consent and the study was approved by the Medical
Ethics Committee of the Leiden University Medical Center,
Leiden, the Netherlands. The START trial was performed to
evaluate the antithrombotic effects of statins.
Participants were included if they were 18 years or older
with a prior (initial or recurrent) confirmed symptomatic
proximal deep vein thrombosis or pulmonary embolism.
Also, they should have stopped their vitamin K antagonist
treatment for one month (to allow anticoagulant drugs to
wear off), as decided by their treating physician. Before
inclusion, we did not check if the ultrasound or CTPA was
negative for VTE. Reasons for exclusion were current use of
statins or other lipid lowering drugs, or contraindications for
rosuvastatin use. All those participants included were ran-
domised to 28 days of treatment with rosuvastatin 20 mg, or
no study medication. Blood samples were collected during
the randomisation visit and at the end of the study period.
Measurements
Blood sampling by venipuncture was performed using the
Vacutainer system (Becton Dickinson), containing sodium
citrate (final concentration 0109 mol/l). Participants’ blood
was drawn between 8:00 a.m. and 3:00 p.m., and at the same
hour of the day at the end of the study for logistical reasons,
but also because of the circadian rhythm of especially clot
lysis time and PAI-1.12–14 Within 3 h, blood samples were
centrifuged at 2500 g for 15 min at 18°C and stored after-
wards at 80°C in our biobank.
To study the plasma fibrinolytic potential, the plasma clot
lysis time was measured by experienced technicians as described
previously.14 Platelet-poor plasma was diluted 17 times in a
buffer (25 mmol/l Hepes, 137 mmol/l sodium chloride,
35 mmol/l potassium chloride, 1% (w/v) BSA, pH 74) at room
temperature, and the diluted plasma (85 ll) was added to wells
of a microtitre plate containing 15 ll of a reaction mixture. The
reaction mixture contained the following components (with the
final concentrations in the assay): tissue factor (TF, Innovin,
1000 times diluted, Dade Behring, Marburg, Germany), calcium
chloride (17 mmol/l), t-PA (30 ng/ml, Actilyse, Boehringer
Ingelheim, Ingelheim am Rhein, Germany) and phospholipid
vesicles (10 lmol/l, Rossix, M€olndal, Sweden). After mixing the
diluted plasma with the reaction mixture on a plate shaker, each
well was covered with 50 ll paraffin oil (Merck, Darmstadt,
Germany) and the microtitre plate was placed into the pre-
heated chamber of the microplate reader (VictorTM, PerkinEl-
mer, Waltham, MA, USA). The optical density at 405 nm was
measured every minute for 300 min at 37°C. The clot lysis time
was measured in duplicate (time from the midpoint of mini-
mum turbidity to maximum turbidity, to the midpoint of maxi-
mum turbidity to minimum turbidity). These midpoints were
calculated using the Shiny app.15,16 The intra- and inter-assay
variation coefficients from our laboratory were previously
shown to be 35% and 65–8%, respectively.14,17 PAI-1 activity
was determined using a TriniLIZE PAI-1 activity bio-im-
munoassay (BIA), according to the instructions of the manufac-
turer (Tcoag, Wicklow, Ireland). Fibrinogen levels (Thrombin
Reagent, Siemens) were measured using the von Clauss method,
plasmin inhibitor levels using a chromogenic assay with
reported units converted from % to U/ml (Stachrom,
Stago,100% = 1 U/ml) and TAFI activity using the Pefakit
chromogenic assay in plasma (Pentapharm, Aesch, Switzerland)
on a Sysmex CS5100 coagulation analyser (Siemens Healthcare
Diagnostics B.V.). In this Pefakit assay, the amounts of TAFI in
each plasma sample were activated by exogenous thrombin and
thrombomodulin. These test results are therefore independent
of the coagulation factors in the sample.
Study aim and endpoints
The primary aim of the present study was to assess the effect
of rosuvastatin use on fibrinolysis and fibrinolysis parame-
ters. The secondary aim was to evaluate the impact of each
individual fibrinolysis parameter on overall plasma fibri-
nolytic potential after rosuvastatin use.
The primary endpoints of this study were plasma fibri-
nolytic potential and levels of fibrinogen, plasmin inhibitor,
PAI-1 and TAFI before and after rosuvastatin and non-rosu-
vastatin use. The secondary endpoints of this study were the
regression coefficient and the explained variance of the indi-
vidual fibrinolysis parameters on a change in the plasma fib-
rinolytic potential after rosuvastatin use.
Data analysis
The general characteristics of the participants are reported as
means and ranges. For the primary endpoint, mean levels with
95% Confidence Interval (CI) of the plasma fibrinolytic poten-
tial and fibrinolysis parameters were calculated at the time of
randomisation and at the end of the study period. All the
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parameters were normally distributed and we compared the
mean values obtained at baseline and after four weeks of treat-
ment. Because more men were randomised to non-rosuvas-
tatin use and participants in this non-rosuvastatin group were
older compared to the rosuvastatin users, we decided a priori
to additionally perform an adjusted analysis for sex and age by
methods of linear regression.
We furthermore prespecified a subgroup analysis in the
group that did not report any signs or symptoms of an infec-
tion during the study, because inflammation leads to a pro-
coagulant state and consequently increased fibrinolysis.18,19
Additionally, we performed a subgroup analysis comparing
participants after an unprovoked or provoked first VTE,
because an etiology including hypercoagulability and recur-
rence rate of VTE is expected to be different among these
groups.20 A two-sided P-value of 005 or lower was consid-
ered to indicate statistical significance.
For the secondary endpoint, results of the individual partici-
pants on change in plasma fibrinolytic potential, fibrinogen,
plasmin inhibitor, PAI-1 and TAFI were standardised by calcu-
lating Z-scores in order to compare the relative strength of the
various fibrinolysis parameters on plasma fibrinolytic poten-
tial. This Z-score is calculated for an observation in a partici-
pant as the number of standard deviations (SD) from the
mean. To determine the relative impact on change of the vari-
ous fibrinolysis parameters on the change in the plasma fibri-
nolytic potential, simple and also multiple linear regression
analyses were performed in the rosuvastatin group. The stan-
dardised regression coefficient for a fibrinolysis parameter
indicates the increase or decrease in SDs of the plasma fibri-
nolytic potential, when that particular fibrinolysis parameter
increases per SD and all other variables in the model are
unchanged. The R2 was calculated, denoting (when multiplied
by 100%) the explained variation of change in plasma fibri-
nolytic potential in rosuvastatin users by the individual, or the
combined change in fibrinolysis parameters. All data was anal-
ysed using ‘IBM SPSS Statistics for Windows, version 25’.
Reporting of this study is in accordance with the CONSORT
statement and the broader EQUATOR guidelines.21
Results
Study population
Between December 2012 and December 2016, a total of 255
participants were randomised: 131 assigned to the rosuvas-
tatin group, and 124 to the non-rosuvastatin group. From
126 participants of the rosuvastatin group, and from 121
participants of the non-rosuvastatin group, blood samples
were available for analysis of plasma fibrinolytic potential,
fibrinogen, plasmin inhibitor, PAI-1 and TAFI. In one partic-
ipant from the rosuvastatin group and in two participants
from the non-rosuvastatin group, PAI-1 levels could not be
measured due to technological failure. Mean age was lower
in rosuvastatin users (57 years, range 19–82) compared to
non-rosuvastatin users (59 years, range 21–81) and the per-
centage of male participants was lower in rosuvastatin users
(54%) compared to non-rosuvastatin users (69%) Table 1.
Other baseline characteristics were balanced. In the rosuvas-
tatin group, mean cholesterol levels were reduced by
196 mmol/l (95% CI 183–209) compared to 019 mmol/l
(95% CI 010–027) in the non-rosuvastatin group, indicat-
ing good adherence to the rosuvastatin treatment.
The effect of rosuvastatin use on fibrinolysis
We found that in the rosuvastatin group, clot lysis time as
indicator of the plasma fibrinolytic potential decreased by
875 min (95% CI 138 to 372), mean fibrinogen levels
were 017 g/l higher (95% CI 004–029), plasmin inhibitor
levels were 005 U/ml lower (95% CI 007 to 002) and
TAFI activity was 477% lower (95% CI 681 to 273) at
the end of study as compared with baseline, but PAI-1 levels
did not differ (mean change 101 IU/ml; 95% CI 390 to
189). (Fig 1 and Table S1). In the non-rosuvastatin group,
plasma fibrinolytic potential and individual fibrinolysis
parameters did not change during follow-up (mean change
clot lysis time 365 min, 95% CI 107 to 339). When we
compared the change in plasma fibrinolytic potential during
follow-up between the rosuvastatin and the non-rosuvastin
group, the change in plasma fibrinolytic potential tended to
be less for rosuvastatin users than for non-rosuvastatin users
Table 1. Baseline characteristics.
Rosuvastatin-users
(n = 126)
Non-rosuvastatin
users (n = 121)
Age (years) 57 (19–82) 59 (21–81)
Male sex 68 (54) 84 (69)
Body mass index (kg/m2) 274 (192–435) 277 (172–432)
Current smoking 18 (14) 17 (14)
Hypertension 24 (19) 21 (17)
Diabetes 3 (2) 0 (0)
Baseline cholesterol
(mmol/l)
561 (295–899) 559 (333–789)
Recurrent venous
thrombosis
10 (8) 8 (7)
Unprovoked venous
thromboembolism
57 (45) 64 (53)
Provoked venous
thromboembolism
69 (55) 57 (47)
Provoked by
Surgery/trauma/
immobilisation
32 (25) 31 (26)
Travel >4 h 22 (18) 14 (12)
Oestrogen use
(% in women)
24 (41) 14 (38)
Pregnancy/puerperium
(% in women)
0 (0) 2 (5)
Malignancy 2 (2) 8 (7)
Categorical variables are denoted as n (%) and continuous variables
as mean (range).
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after adjustment for sex and age (579 min, 95% CI 145
to 291) (Fig 1 and Table S1). For the fibrinolysis parame-
ters, the plasmin inhibitor levels and TAFI concentration
were both lower at the end of the study in rosuvastatin users
compared to non-rosuvastatin users (004 U/ml, 95% CI
008 to 0003 and 378%,95% CI 663 to 092,
respectively). The mean change in fibrinogen and PAI-1
levels did not differ between groups.
In the subgroup analysis of patients who did not report
any symptoms or signs of infection (n = 239), results in both
groups were similar to the main analysis. When we com-
pared results of participants after an unprovoked or pro-
voked VTE, the mean change in plasma fibrinolytic potential
appeared larger in the group of rosuvastatin users after a
provoked VTE as compared to the unprovoked group
(113 min; 95% CI 190 to 359, compared to
567 min; 95% CI 119 to 057). For fibrinogen and
TAFI, change in levels or concentration at the end of the
study in rosuvastatin users was also more evident in the sub-
group after provoked VTE (Table S2).
Figure 1. Effects of rosuvastatin on measures of fibrinolysis.
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The impact of individual fibrinolysis parameters on
change in plasma fibrinolytic potential in rosuvastatin
users
Among the fibrinolysis parameters, the only change in plas-
min inhibitor was associated with change in plasma fibri-
nolytic potential in rosuvastatin users (Table 2). The
regression coefficient of this association was 018 (95% CI
0002–0352). The explained variance in this model was 3%
(R2 003). Including all the fibrinolytic parameters in a mul-
tiple regression model increased the explained variance of
change in plasma fibrinolytic potential to 5% (R2 005).
Discussion
Our randomised study in those participants with prior VTE
who stopped anticoagulant treatment showed that four weeks
of 20 mg/day rosuvastatin use led to an increased plasma fib-
rinolytic potential, whereas non-use did not lead to increased
fibrinolysis. The difference in change in fibrinolytic potential
in users versus non-users did, however, not reach statistical
significance. Among the fibrinolysis parameters, plasmin
inhibitor and TAFI decreased during the use of rosuvastatin,
and the changes in rosuvastatin users compared to non-users
also differed significantly. Fibrinogen levels were increased
after four weeks of rosuvastatin use, but PAI-1 levels did not
change (Figure S1). The variance in change in plasma fibri-
nolytic potential between the baseline and the end of the
study was explained for 3% by the change in plasmin inhibi-
tor and not by other individual fibrinolysis parameters.
Notably, there is a relationship between clot formation and
lysis,22 suggesting that increased fibrinolytic potential by
rosuvastatin could be secondary to decreased coagulation.
However, we also found decreased levels of TAFI and plas-
min inhibitor, which support a direct pro-fibrinolytic effect
of rosuvastatin. The changes in fibrinolytic potential and the
individual fibrinolysis parameters in rosuvastatin users could
be clinically relevant, though this should be investigated in
prospective larger studies.
This is the first study in participants with prior VTE,
showing that 28 days use of rosuvastatin increases plasma
fibrinolytic potential and lowers plasma levels of TAFI and
plasmin inhibitor. Direct effects on plasma fibrinolytic poten-
tial were also measured earlier after a very short use
(three days) of atorvastatin in a non-randomised study.23
Another before-after study evaluated plasma fibrinolytic
potential after simvastatin therapy, and presented a mean
shortening in clot lysis time of 129 min after a three‑month
treatment with simvastatin 40 mg.24 Reduced plasma fibri-
nolytic potential (i.e. longer clot lysis times) has been shown
to be associated with a higher risk of VTE.3,6,7 Our findings
corroborate fibrinolytic activity being increased by rosuvas-
tatin and that it might therefore decrease the risk of recur-
rent VTE.
Results on the individual fibrinolytic parameters are pri-
marily in line with the results on plasma fibrinolytic poten-
tial. Specifically, lower levels of plasmin inhibitor and TAFI
will lead to reduced inhibition of fibrinolysis, consequently
resulting in shorter clot lysis times and therefore increased
global fibrinolytic potential. Decreased TAFI levels were also
previously observed in 35 patients with hyperlipidaemia after
eight weeks of treatment with simvastatin and in another
study in which 44 patients with hypercholesterolaemia were
treated with atorvastatin.25,26 Studies on plasmin inhibitor
are scarce with only one comparable study on 24 patients
with primary dyslipidaemia treated with simvastatin, and 18
patients treated with pravastatin for 12 weeks.27 In the sim-
vastatin group, plasmin inhibitor did not change after treat-
ment, but in the pravastatin group the levels decreased.
Remarkably, in our study PAI-1 levels did not change after
rosuvastatin use even though we expected this fibrinolytic
parameter to have a high impact on the plasma fibrinolytic
potential.28 Fibrinogen levels were also unexpectedly higher
after rosuvastatin use in our study. Since fibrinogen is associ-
ated with pro-inflammatory and pro-coagulants effects, one
would expect that statins would decrease fibrinogen levels. In
a meta-analysis of 14 other studies, including patients with
high cholesterol or stable coronary disease, no effect of statin
treatment on PAI-1 levels and fibrinogen was found either.29
For rosuvastatin specifically, a reduction in fibrinogen levels
after six months of treatment was shown in 24 patients with
rheumatoid arthritis and in 100 patients with metabolic
Table 2. Mean impact in change in plasma fibrinolytic potential with one SD increase in fibrinolytic parameter between baseline and end of
study in rosuvastatin users.
Simple model* Multiple model†
b (95%CI) R2 b (95%CI) R2
Change in fibrinogen (g/l) 002 (020 to 016) 000 004 (022 to 014) 005
Change in plasmin inhibitor (U/ml) 018 (0002 to 035) 003 018 (0003 to 036)
Change in plasminogen activator inhibitor-1(PAI-1) (IU/ml) 0001 (018 to 018) 000 004 (014 to 021)
Change in thrombin activatable fibrinolysis inhibitor (TAFI) (%) 013 (031 to 004) 002 126 (030 to 005)
SD, standard deviation; CI, confidence interval.
*In each of the four different single models, plasma fibrinolytic potential was the dependent variable, and only one of the fibrinolytic parameters
was the independent variable.
†Plasma fibrinolytic potential was the dependent variable and all four fibrinolytic parameters simultaneously were independent variables.
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syndrome, but in another study, fibrinogen levels did not
change after three months in 17 patients with type 2 dia-
betes.30–32 D-dimer levels, a FDP generated in the blood clot
during fibrinolysis in vivo, were already measured in the
START study. Measured D-dimer levels were higher at the
end of the study in non-rosuvastatin users, but remained
unchanged in the rosuvastatin group.11 After withdrawal of
anticoagulant treatment, D-dimer levels normally increase,
which is called the rebound phenomenon.33,34 D-dimer levels
are the result of the amount of available fibrin and the fibri-
nolytic potential. Rosuvastatin is expected to lower fibrin
levels by reducing clotting factors and by its anti-inflamma-
tory effects, and to increase the fibrinolytic potential.9,11,35
Because of the lack of increase in D-dimer levels in rosuvas-
tatin users during follow-up, we expect that the effect of low-
ering fibrin levels is stronger than the effect of increasing
fibrinolytic potential.
Interestingly, in the subgroup analysis results on increased
plasma fibrinolytic potential, decreased plasmin inhibitor and
TAFI seemed to be more robust after a provoked VTE than
unprovoked VTE. Karasu et al., on the other hand, reported
that provoked VTE showed a 15-fold increased risk of VTE
in the presence of hypofibrinolysis, whereas for unprovoked
VTE, hypofibrinolysis was associated with a higher 21-fold
increased risk.36 This contradiction might be explained by a
different or stronger additional impact of rosuvastatin use on
hypofibrinolysis in patients after provoked VTE rather than
unprovoked VTE, or a reduced impact in our study for per-
forming this subanalysis.
To evaluate the impact of each individual fibrinolysis
parameter on overall plasma fibrinolytic potential after rosu-
vastatin use, we performed an additional regression analysis.
Results suggest minor impact of change of individual fibri-
nolysis parameters with only a small significant impact of
plasmin inhibitor. This was unexpected, because in another
study, TAFI and PAI-1 levels explained the majority of the
variance in clot lysis time.28 However, in our analysis we
only evaluated the change in parameters according to the
change in plasma fibrinolytic potential.
Some aspects of this study warrant comment. The START
study was open label and we noticed a difference in the dis-
tribution of sex and age between the groups. However, since
we evaluated fibrinolysis parameters and we decided a priori
to correct our analysis for these possible confounders, it is
unlikely that both factors influenced our results. Another
aspect is that we only tested the effect of rosuvastatin, a
hydrophilic type of statin. Hydrophilic statins, such as
pravastatin and rosuvastatin, have different properties to
lipophilic statins, such as simvastatin, atorvastatin and fluvas-
tatin. Cellular uptake of hydrophilic types of statins, for
example, is only present in hepatocytes but not in extrahep-
atic cells, whereas lipophilic statins penetrate cell membranes
and enter cells in any organ.37 The exact effect on fibrinolysis
might therefore be different for hydrophilic statins than for
rosuvastatin. Nevertheless, our findings on increased
fibrinolysis after rosuvastatin treatment underline the sugges-
tion that statins could be prescribed to patients with prior
VTE who are considered to be at high risk of anticoagula-
tion-related bleeding.
In conclusion, we found that in participants with prior
VTE who stopped anticoagulant treatment, four weeks of
rosuvastatin use led to an increased plasma fibrinolytic
potential, decreased plasmin inhibitor and TAFI and higher
fibrinogen levels compared to non-statin users, whereas PAI-
1 levels did not change. Variance in change in plasma fibri-
nolytic potential could only be explained for a small part by
change in plasmin inhibitor and not by the other individual
fibrinolysis parameters. This increase in fibrinolytic potential
and formerly reported anticoagulant effects after rosuvastatin
treatment support the need for further studies on the possi-
ble role for statins in the secondary prevention of VTE.
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Fig S1. Schematic overview of effects of rosuvastatin
20 mg/day on fibrinolysis.
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Table S1. Effects of rosuvastatin on measures of fibrinoly-
sis.
Table S2. Effects of rosuvastatin use on measures of fibri-
nolysis, separated into subgroups of participants with unpro-
voked or provoked venous thromboembolism.
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